RxDoctor Payments Data

David Jue, MD

Internal Medicine · Napa, CANPI 1467470468

Payments from drug & device makers

$760in general payments, 2019–2025

Across 40 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$111
  • AbbVie$101
  • Novo Nordisk$95
  • Astellas Pharma US Inc$80
  • Amgen$71
  • Teva Pharmaceuticals USA, Inc.$56
  • plus $246 from 11 others

What the payments were for

  • Food & beverage$760100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$760 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$292,747
Medicare patients
277
Services billed
7,782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban127$102,317
JardianceEmpagliflozin38$48,062
OzempicSemaglutide27$29,520
FarxigaDapagliflozin Propanediol16$21,840
XareltoRivaroxaban15$21,093
Spiriva RespimatTiotropium Bromide22$16,878
JanuviaSitagliptin Phosphate18$15,281
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$13,085
GemtesaVibegron16$11,407
Wixela InhubFluticasone Propion/Salmeterol21$4,924
Nebivolol Hcl38$4,822
Atorvastatin Calcium245$3,727
Tadalafil12$3,705
Celecoxib83$3,319
Potassium Chloride42$3,185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$13$105,067143 claims
Boehringer IngelheimJardiance, Spiriva Respimat$111$64,94060 claims
Novo NordiskOzempic$95$29,52027 claims
MerckJanuvia$14$15,28118 claims
AbbVieSynthroid$101$1,19327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Napa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →